Competition is expected to expand beyond P-CAB to PPI

HK inno.N and Daewoong Pharmaceutical are competitively expanding the indication of P-CAB series gastroesophageal reflux disease treatment. On top of that, Jeil Pharmaceutical is planning to join the competition by operating two clinical trials at the same time to launch the third gastroesophageal reflux disease treatment. The pharmaceutical industry predicts that competition in the gastroesophageal reflux disease treatment market, including P-CAB-based drugs as well as PPI-based drugs, will intensify in the future. On the 22nd, Daewoong Pharmaceutical announced that the indication of Fexclue, a new drug for treating gastroesophageal reflux disease,